ASH 2023 | Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana, MD, Stanford University, Stanford, CA, presents findings from a retrospective study comparing outcomes of idecabtagene vicleucel (ide-cel) therapy in multiple myeloma patients with renal impairments versus those without. The study reveals comparable safety profiles between the two groups, with an initial rise in cytopenias in renal-impaired patients, which equalized by day 90 of treatment. Additionally, the efficacy of ide-cel remains consistent, positioning this CAR-T therapy as a safe and effective option for MM patients with renal impairments. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda, Pfizer
Research Funding: Magenta Therapeutics, BMS, Allogene, Janssen, Novartis
